The effect of anthracycline-based chemotherapy on endothelial function and arterial stiffness in breast cancer patients

Μaria Anastasiou(National and Kapodistrian University of Athens), Dimitris Tousoulis(National and Kapodistrian University of Athens), George-Angelo Papamikroulis(National and Kapodistrian University of Athens), Maria Gazouli(National and Kapodistrian University of Athens), Gerasimos Siasos(Brigham and Women's Hospital), Flora Zagouri(National and Kapodistrian University of Athens), Panagiotis Theofilis(General Hospital of Nikea), Athina Goliopoulou(National and Kapodistrian University of Athens), Amanda Psyrri(National and Kapodistrian University of Athens), Evangelos Oikonomou(National and Kapodistrian University of Athens), D Papatheodoridi(Alexandra Hospital), Theodoros Pesiridis(National and Kapodistrian University of Athens)
European Heart Journal
November 1, 2023
10.1093/eurheartj/ehad655.2675
Cited by 0

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across Regions
|European Journal of Heart Failure|2016|781
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148